Osteosarcoma and PTHrp
Parathyroid hormone receptor 1
(PTHR1) is a prognostic indicator
in canine osteosarcoma
PTHrp expression in osteosarcoma tumor tissue is associated with a more guarded prognosis.
Osteosarcoma metastasis after initial treatment
Prognosis for dogs with stage III osteosarcoma following treatment with amputation and chemotherapy with and without metastasectomy
Dogs receiving surgery to remove metastatic pulmonary nodules who met criteria as good candidates lived longer (8 months) than those who did not (1.5 months) after diagnosis of metastasis.
Criteria for surgery included:
less than 3 pulmonary nodules
Disease free > 9 months after amputation
Stage III OSA
Evaluation of survival time
in dogs with stage III osteosarcoma
that undergo treatment: 90 cases (1985–2004)
Dogs with metastatic osteosarcoma at the time of initial diagnosis lived longest when treated palliatively with radiation and chemotherapy.
surgery: 3 days
NSAIDs alone: 1 month
Surgery and chemotherapy: 3 months
Radiation and chemotherapy: 4 months
Hemangiosarcoma and time to first Chemotherapy
Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy
Starting chemotherapy within 3 weeks of splenectomy is important for survival duration in dogs with stage II or lower splenic hemangiosarcoma.
Neuroimmune Regulation in Cancer Therapy
Neuroimmune Regulation of Surgery-Associated Metastases
Broad targeting of angiogenesis for cancer prevention and therapy
Inhibition of tumor angiogenesis has become a clinical anti-cancer strategy in line with chemotherapy, radiotherapy and surgery, which underscore the critical importance of the angiogenic switch during early tumor development.